http://orcid.org/0000-0002-6465-0972
References
- Adiamah A, Psaltis E, Crook M, et al. A systematic review of the epidemiology, pathophysiology and current management of hyperlipidaemic pancreatitis. Clin Nutr. 2017;1–13. DOI:10.1016/j.clnu.2017.09.028
- Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis–2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62:102–111.
- Scherer J, Singh VP, Pitchumoni CS, et al. Issues in hypertriglyceridemic pancreatitis an update. J Clin Gastroenterol. 2014;48:195–203.
- Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis. JAMA Intern Med. 2016;176:1834–1842.
- Henneman P, Schaap FG, Rensen PC, et al. Estrogen induced hypertriglyceridemia in an apolipoprotein AV deficient patient. J Intern Med. 2008;263:107–108.
- Ferns G, Keti V, Griffin B. Investigation and management of hypertriglyceridaemia. J Clin Pathol. 2008;61:1174–1183.
- Shah AS, Wilson DP. Primary hypertriglyceridemia in children and adolescents. J Clin Lipidol. 2015;9(5 Suppl):S20–S208.
- Blackett PR, Wilson DP, McNeal CJ. Secondary hypertriglyceridemia in children and adolescents. J Clin Lipidol. 2015;9:S29–S40.
- Dragoman M, Curtis KM, Gaffield ME. Combined hormonal contraceptive use among women with known dyslipidemias: a systematic review of critical safety outcomes. Contraception. 2016;94:280–287.
- Abraham M, Mitchell J, Simsovits D, et al. Hypertriglyceridemic pancreatitis caused by the oral contraceptive agent estrostep. J Intensive Care Med. 2015;30:303–307.
- The HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203–212.
- Ito MK. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature. Atherosclerosis. 2015;242:647–656.